gvax cancer vaccine composed whole tumor cells genetically modified secrete immune stimulatory cytokine granulocytemacrophage colonystimulating factor gmcsf irradiated prevent cell division product exists autologous patient specific allogeneic nonpatient specific gvax developed around glenn dranoff cancer researcher whitehead institute cambridge therapy initially developed public gene therapy company called somatix acquired cell company took vaccine phase iii trials however trials halted due apparent lack cell genesys continued development however august due funding difficulties company announced merging biosante biosante sold gvax program aduro biotech company based berkeley aduro biotech merged chinook therapeutics inc form chinook aduro biotech currently phase ii gvax pancreatic cancer company also trialing combination gvax httpsenwikipediaorgwikigvax